Nanomedical Diagnostics declares commercialization of graphene biosensor

Nanomedical Diagnostics, a U.S-based biotech company developing and commercializing bioelectronics for use in research and diagnostics, launched its first product, AGILE Research, a label-free, quantitative, low-cost biosensor for small molecule and protein analysis. The product is entering beta testing this fall and planned for commercial release in early 2016.

AGILE Research is based on graphene biological field effect transistor (BioFET) technology. Its vision is enabling personalized healthcare by improving diagnostic ease, speed, and cost through cutting-edge capabilities. Nanomed’s current focus is finalizing AGILE Research product design and will be evaluating its performance with the Centers for Disease Control and Prevention (CDC) and Stanford University. The CDC and Nanomedical Diagnostics are entering into a Cooperative Research and Development Agreement to evaluate direct electronic detection of Borrelia burgdorferi antigens for a new Lyme disease diagnostic system. Lyme disease research is also a focal point in the Stanford beta test.